We transiently transfected HEK293T cells with Myc-tagged murine Tet2 and assessed 5-mC and 5-hmC levels by immunocytochemistry ([Fig. 1](#F1){ref-type="fig"}, [Suppl. Figs. 1--4](#SD3){ref-type="supplementary-material"}). Myc-Tet2-expressing cells displayed a strong increase in 5-hmC staining and a concomitant decrease in 5-mC staining in the nucleus ([Fig. 1b, c](#F1){ref-type="fig"}, quantified in [Suppl. Fig. 4](#SD3){ref-type="supplementary-material"}). In contrast, 5-hmC was undetectable or barely detected in nuclei of cells expressing mutant Tet2 with H1302Y, D1304A substitutions in the signature HxD motif[@R1],[@R12],[@R17] involved in coordinating Fe^2+^, and there was no obvious decrease in nuclear 5-mC staining ([Fig. 1b, c](#F1){ref-type="fig"}, [Suppl. Fig. 4](#SD3){ref-type="supplementary-material"}). These studies confirm[@R13] that Tet2 is a catalytically active enzyme that converts 5-mC to 5-hmC in genomic DNA.

Mutations in TET2 residues H1881 and R1896, predicted to bind Fe^2+^ and 2OG, respectively, have been identified repeatedly in patients with myeloid malignancies[@R4],[@R5],[@R7],[@R10]. HEK293T cells expressing Tet2 mutants H1802R and H1802Q ([Fig. 1a](#F1){ref-type="fig"}, [Suppl. Fig. 2](#SD3){ref-type="supplementary-material"}) showed greatly diminished 5-hmC staining and no loss of 5-mC staining, consistent with participation of this residue in catalysis ([Fig. 1b, c](#F1){ref-type="fig"}, [Suppl. Fig. 4a, b](#SD3){ref-type="supplementary-material"}). We analysed missense mutations identified in TET2 in our own ([Suppl. Table S1](#SD4){ref-type="supplementary-material"}) and other[@R3]--[@R6], [@R11] studies (P1367S, W1291R, G1913D, E1318G and I1873T). HEK293T cells expressing Tet2 mutants P1287S, W1211R or C1834D ([Suppl. Figs. 2, 3a](#SD3){ref-type="supplementary-material"}) displayed low 5-hmC staining and strong 5-mC staining ([Suppl. Figs. 3b, 3c, 4c, 4d](#SD3){ref-type="supplementary-material"}), suggesting a role for these residues in the integrity of the catalytic or DNA binding domains. Cells expressing Tet2 R1817S/M ([Fig. 1a](#F1){ref-type="fig"}, [Suppl. Figs. 2, 3a](#SD3){ref-type="supplementary-material"}) were positive for 5-hmC staining but changes in 5-mC staining could not be reliably assessed ([Figs. 1b,c](#F1){ref-type="fig"}, [Suppl. Figs. 3b, 3c, 4](#SD3){ref-type="supplementary-material"}).

To quantify these findings, we developed dot blot assays to detect 5-hmC in genomic DNA ([Suppl. Fig. 5](#SD3){ref-type="supplementary-material"}). In the first assay format, the blot was developed with a specific antiserum to 5-hmC ([Suppl. Fig. 5b](#SD3){ref-type="supplementary-material"}, *left*), whose ability to recognize 5-hmC depended strongly on the density of 5-hmC in DNA ([Suppl. Fig. 5c](#SD3){ref-type="supplementary-material"}, *top*). We therefore developed a more sensitive and quantitative assay in which DNA was treated with bisulfite to convert 5-hmC to cytosine 5-methylenesulfonate (CMS) [@R14] ([Suppl. Fig. 5a](#SD3){ref-type="supplementary-material"}), after which CMS was measured with a specific anti-CMS antiserum ([Suppl. Fig. 5b](#SD3){ref-type="supplementary-material"}, *right*). Unlike anti-5-hmC which reacted efficiently only with DNA containing high densities of 5-hmC, the anti-CMS antiserum recognized DNA with an average of only a single 5-hmC per 201 bp ([Suppl. Fig. 5c](#SD3){ref-type="supplementary-material"}, *bottom*). This lack of density dependence allowed us to plot the signal obtained with 2-fold dilutions of a standard oligonucleotide containing a known amount of 5-hmC against the amount of CMS obtained after bisulfite conversion. We assumed 100% conversion efficiency[@R15] and used the linear portion of the standard curve to compute the amount of CMS, and therefore 5-hmC, in the DNA samples (e.g. see [Fig. 2a](#F2){ref-type="fig"}, *right*).

To assess 5-hmC levels, we obtained uniform populations of Tet2-expressing HEK293T cells by transfection with Tet2-IRES-CD25 plasmid followed by magnetic isolation of CD25-expressing cells[@R1]. Wild type and mutant Tet2 proteins were expressed at comparable levels ([Fig. 1d](#F1){ref-type="fig"}, [Suppl. Fig. 3d](#SD3){ref-type="supplementary-material"}). Anti-5-hmC/ CMS dot blots of genomic DNA revealed, as expected, that 5-hmC was barely detectable in DNA from cells transfected with empty vector; DNA from cells expressing wild type Tet2 showed a substantial increase in 5-hmC and a corresponding decrease in 5-mC; and DNA from cells expressing the HxD mutant Tet2 protein had very low 5-hmC ([Fig. 1e](#F1){ref-type="fig"}, [Suppl. Figs. 3e, 6](#SD3){ref-type="supplementary-material"}). DNA from cells expressing 7 of the 9 mutant Tet2 proteins tested \-- H1802Q/R, R1817S/M, W1211R, P1287S and C1834D \-- contained significantly less 5-hmC than DNA from cells expressing wild type Tet2 ([Fig. 1e](#F1){ref-type="fig"}, [Suppl. Figs. 3e, 6](#SD3){ref-type="supplementary-material"}), confirming our previous conclusion that these mutations impair enzymatic activity.

We measured 5-hmC (CMS) levels in genomic DNA extracted from bone marrow or blood (with \>20% immature myeloid cells) of 88 patients with myeloid malignancies and 17 healthy controls ([Suppl. Table S1](#SD4){ref-type="supplementary-material"}). In blinded experiments, DNA was treated with bisulfite and CMS levels were evaluated. *TET2* mutations were strongly associated with low genomic 5-hmC ([Fig. 2](#F2){ref-type="fig"}, [Suppl. Fig. 7a](#SD3){ref-type="supplementary-material"}). To confirm these conclusions in a statistically rigorous fashion, we tested samples for which a sufficient amount of DNA was available to make independent dilutions in triplicate, so that a median and standard deviation for 5-hmC (CMS) levels in each patient could be derived ([Suppl. Fig. 7b](#SD3){ref-type="supplementary-material"}). Analysis of DNA from 9 healthy donors and 41 patients (28 with wild type *TET2* and 13 with *TET2* mutations, [Suppl. Table S1](#SD4){ref-type="supplementary-material"}) revealed a strong, statistically significant correlation of *TET2* mutations with low 5-hmC ([Fig. 2c](#F2){ref-type="fig"}). In contrast, samples from patients with wild type *TET2* showed a bimodal distribution, with 5-hmC levels ranging from \~0.4 to \~3.8 pmol/µg DNA ([Fig. 2c](#F2){ref-type="fig"}; [Suppl. Fig. 7](#SD3){ref-type="supplementary-material"}; also see [Fig. 4](#F4){ref-type="fig"}).

We examined *Tet2* expression in haematopoietic cell subsets isolated from bone marrow and thymus of C57BL/6 mice ([Suppl. Figs. 8, 9](#SD3){ref-type="supplementary-material"}). *Tet2* mRNA was highly expressed in lineage-negative (Lin^−^) Sca-1^+^c-Kit^hi^ multipotent progenitors (LSK), at levels similar to those in embryonic stem cells (ESC). Expression was maintained at high levels in myeloid progenitors (common myeloid progenitors, CMPs, and granulocyte-monocyte progenitors, GMPs), was low in mature granulocytes (Gr-1^+^Mac-1^+^) and high in monocytes (Gr-1^−^ Mac-1^+^) ([Suppl. Fig. 9a](#SD3){ref-type="supplementary-material"}, *middle panel*).

To test the role of Tet2 in myelopoiesis, we transduced bone marrow stem/progenitor cells with *Tet2* shRNA ([Suppl. Fig. 10a](#SD3){ref-type="supplementary-material"}), effectively downregulating *Tet2* mRNA and protein relative to control cells transduced with empty vector or scrambled shRNA ([Fig. 3a, b](#F3){ref-type="fig"}) (refer to [Suppl Fig. 10 b](#SD3){ref-type="supplementary-material"} for choice of Tet2 shRNA). Tet2 depletion promoted expansion of Mac-1^+^ F4/80^+^ and Mac1^+^ CD115^+^ monocyte/macrophage cells in the presence of G-CSF or GM-CSF, cytokines that support granulocyte and granulocyte/ monocyte development respectively, but not in the presence of M-CSF, which promotes growth of monocytic progenitors ([Fig. 3c](#F3){ref-type="fig"}; [Suppl. Fig. 10d](#SD3){ref-type="supplementary-material"}). Simultaneous treatment with GM-CSF and M-CSF, or GM-CSF and G-CSF, also led to increased numbers of monocyte/macrophage cells ([Fig. 3c](#F3){ref-type="fig"}). These results indicate that Tet2 plays an important role in normal myelopoiesis. However, Tet2 does not markedly influence short-term proliferation of myeloid-lineage cells: when shRNA-transduced Lin^−^ cells were cultured in the presence of GM-CSF and pulse-labeled with BrdU, Tet2 depletion promoted monocyte/ macrophage expansion but CD115^+^ (M-CSFR^+^) cells from the two cultures showed no difference in acute BrdU incorporation ([Suppl. Fig. 11](#SD3){ref-type="supplementary-material"}).

We asked whether 5-hmC levels in tumour samples correlated with DNA methylation status. A histogram of normalised values from 88 patients and 17 healthy individuals showed the expected bimodal distribution (see [Online Methods](#SD1){ref-type="supplementary-material"}): healthy controls and most patient samples with wild type *TET2* had high 5-hmC, while the majority of patient samples with mutant *TET2* had low 5-hmC ([Fig. 4b](#F4){ref-type="fig"}). The DNA methylation status of 62 samples was interrogated at 27,578 CpG sites. As expected[@R16], the resulting histograms were strikingly bimodal, with sites within and outside CpG islands showing low and predominantly high methylation respectively ([Fig. 4c](#F4){ref-type="fig"}). Comparison of 28 control samples with 24 high 5-hmC tumour samples (22 *TET2* wild type, 2 *TET2* mutant) showed no significant difference in DNA methylation; in contrast comparison of the control samples with 29 low 5-hmC tumour samples (7 *TET2* wild type, 22 *TET2* mutant) yielded 2512 differentially methylated sites, of which the majority (2510 sites) were hypomethylated compared to controls ([Fig. 4d](#F4){ref-type="fig"}, [Suppl. Table S2](#SD5){ref-type="supplementary-material"} online). Thus TET2 loss-of-function is predominantly associated with decreased methylation at CpG sites.

To summarise, our studies demonstrate a strong correlation between myeloid malignancies and loss of TET2 catalytic activity. The leukemia-associated missense mutations associated with diminished 5-hmC levels provide clues to the structure of the TET2 catalytic domain. The W1211R, P1287S and C1834D mutations affect positions that are highly conserved within the catalytic domain of the TET subfamily of dioxygenases[@R2]: W1211 is located at the beginning of the strand just N-terminal to the core of the DSBH, and is predicted to constitute part of the "mouth" of the active site pocket of the enzyme; P1287 is predicted to stabilize the conformation of the junction between the N-terminal helix and the first core strand of the DSBH; and G1913/ C1834 is predicted to be the N-terminal capping residue of a helix that lines the "mouth" of the DSBH and potentially interacts with substrate DNA[@R2]. The E1238G mutation had no detectable effect on 5-hmC production in our overexpression assays, however, the patient with this mutation also showed CN-LOH spanning 4q24, a feature that likely contributes to the significant reduction in 5-hmC levels observed in the bone marrow.

Low 5-hmC levels were observed in a subset of patients with apparently wild type *TET2*, whose clinical phenotypes resembled those of patients with mutant *TET2*. In several of these patients, TET2 mRNA expression was not significantly different from controls; mutations in other TET proteins have not been described ([Suppl. Text](#SD2){ref-type="supplementary-material"}). Some patients in the wild type *TET2*/ low 5-hmC category may harbour mutations in regulatory or partner proteins for TET2, or in *cis*-regulatory regions controlling *TET2* mRNA expression. Alternatively, the primary event in some of these patients may be CpG hypomethylation, resulting in decreased 5-hmC secondary to depletion of the substrate, 5-mC.

There is little consensus on whether *TET2* mutations correlate with clinical outcome. One study reported an association with decreased survival in AML[@R4], whereas others report little prognostic value in MPN diseases[@R7],[@R10],[@R12]. Assays for 5-hmC may increase our options for the molecular classification of myeloid malignancies, making it possible to ask whether patients with high or low levels of genomic 5-hmC show differences in disease progression or therapeutic response. Notably, histone deacetylase and DNA methyltransferase inhibitors show clinical efficacy in patients with CMML and AML[@R17]; and genomic 5-hmC levels could potentially be a useful prognostic indicator or predictor of patient responses or refractoriness to "epigenetic" therapy with demethylating agents.

DNA methylation is highly aberrant in cancer[@R18]--[@R20]. Since TET operates on 5-mC, we were surprised to find that TET2 loss-of-function in myeloid tumours was associated with widespread hypomethylation rather than the expected hypermethylation at differentially-methylated CpG sites. Tumour samples with low 5-hmC may have expanded cells with localized hypomethylation at these sites; or TET2 may control DNA methylation indirectly, for instance by regulating the expression or recruitment of one or more DNA methyltransferases, perhaps via 5-hmC-binding proteins. Alternatively, if TET2 and 5-hmC are required for cells to exit the stem cell state, loss of TET2 function in myeloid neoplasms may reactivate a stem-like state characterized by generalized hypomethylation and consequent genomic instability[@R21],[@R22]. Indeed, hypomorphic DNMT1 mutations associated with genome-wide DNA hypomethylation skew haematopoietic differentiation toward myelo-erythroid lineages[@R23], and promote the development of aggressive T cell lymphomas due to activation and insertion of endogenous retroviruses[@R24],[@R25]. Further studies of the role of TET2 in haematopoietic differentiation should uncover the relation between TET2 loss-of-function, DNA methylation changes and myeloid neoplasia.

Methods Summary {#S1}
===============

Patient samples {#S2}
---------------

Genomic DNA was extracted from bone marrow/ peripheral blood samples from healthy donors and patients with MDS, MDS/MPN, primary and secondary AMLs. Clinical features and other detailed information pertaining to the patient samples are summarized in [Suppl. Table 1](#SD4){ref-type="supplementary-material"}.

Quantitative analysis of 5-hmC and CMS levels using dot-blot {#S3}
------------------------------------------------------------

For CMS detection, genomic DNA was treated with sodium bisulfite using the EpiTect Bisulfite kit (QIAGEN). DNA samples were denatured and 2-fold serial dilutions were spotted on a nitrocellulose membrane in an assembled Bio-Dot apparatus (Bio-Rad). The blotted membrane was washed, air-dried, vacuum-baked, blocked, and incubated with anti-5-hmC or anti-CMS antibody (1:1,000) and HRP-conjugated anti-rabbit IgG secondary antibody. To ensure equal spotting of total DNA on the membrane, the same blot was stained with 0.02% methylene blue in 0.3 M sodium acetate (pH 5.2). To compare results obtained in different experiments, we used the normalisation procedure described in [Online Methods](#SD1){ref-type="supplementary-material"} (see [Figs. 4a, b](#F4){ref-type="fig"}, which incorporate data from [Fig. 2](#F2){ref-type="fig"} and [Suppl. Fig. 6](#SD3){ref-type="supplementary-material"}).

Methylation analysis {#S4}
--------------------

The DNA methylation status of bisulfite-treated genomic DNA was probed at 27,578 CpG dinucleotides using the Illumina® Infinium® 27k array (Illumina, San Diego, CA)[@R26]. Methylation status was calculated from the ratio of methylation-specific and demethylation-specific fluorophores (β-value) using BeadStudio® Methylation Module (Illumina, San Diego, CA). We removed sites on the Y and X chromosomes from the analysis because of inconsistent methylation status with respect to gender (a known problem based on communication with Illumina. Calculations are based on β values, which correspond to the methylation status of a site ranging from 0 to 1, returned by Illumina\'s BeadStudio software. We tested sites for differential methylation using an empirical Bayes approach employing a modified t-test (limma). The false discovery rate (FDR) is controlled at a level of 5% by the Benjamini-Hochberg correction.
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![The catalytic activity of Tet2 is compromised by mutations in predicted catalytic residues\
**a**, Schematic representation of TET2. The catalytic core region contains the cysteine-rich (Cys-rich) and double-stranded beta-helix (DSBH) domains. Three signature motifs conserved among 2OG- and Fe^2+^-dependent dioxygenases are shown[@R1],[@R2]. Substitutions in the HxD signature that impair the catalytic activity of TET1[@R1], leukemia-associated mutations in the C-terminal signature motifs, and corresponding substitutions introduced into murine Tet2 are indicated.\
**b**, Tet2 expression results in increased 5-hmC by immunocytochemistry. HEK293T cells transfected with Myc-tagged wild type and mutant Tet2 were co-stained with antibody specific for the Myc epitope (red) and antiserum against 5-hmC (green). DAPI (blue) indicates nuclear staining.\
**c**, Tet2 expression results in loss of nuclear 5-mC staining. HEK293T cells transfected with wild type and mutant Myc-tagged Tet2 were co-stained with antibody specific for the Myc epitope (green) and antiserum against 5-mC (red).\
**d**, Equivalent expression of wild type and mutant Myc-Tet2. CD25^+^ cells were isolated from HEK293T cells transfected with bicistronic Tet2-IRES-human CD25 plasmids, and Tet2 expression in whole cell lysates was detected by immunoblotting with anti-Myc. β-actin serves as a loading control.\
**e**, Genomic DNA purified from CD25^+^ HEK293T cells over-expressing wild type or mutant Tet2 was treated with bisulfite to convert 5-hmC to CMS ([Suppl. Fig. 5a](#SD3){ref-type="supplementary-material"}). CMS was quantified by dot blot assay using anti-CMS and a synthetic bisulphite-treated oligonucleotide containing a known amount of CMS. As positive and negative controls, we included DNA from CD25^+^ HEK293T cells transfected with TET1 catalytic domain (TET1-CD) or TET1-CD with mutations in the HxD motif (TET1-CD-HxDmut)[@R1].](nihms247005f1){#F1}

![TET2 mutational status correlates with 5-hmC levels in patients with myeloid malignancies\
**a**, Quantification of 5-hmC by anti-CMS dot blot. *Left*, A representative dot blot of genomic DNA isolated from bone marrow aspirates of patients with MDS/MPN and *TET2* mutational status as indicated. A synthetic oligonucleotide with a known amount of CMS was used as standard. *Right*, The linear portion of the standard curve was used to estimate the amount of 5-hmC in DNA from patient samples.\
**b**, Bar graph of data from Fig. 2a. The three patients with *TET2* mutations show lower 5-hmC levels than the three patients with wild type *TET2*. Error bars indicate standard deviation (n=3).\
**c**, Correlation of 5-hmC levels with *TET2* mutational status. CMS levels in bone marrow samples from healthy donors and patients with myeloid malignancies ([Suppl. Table S1](#SD4){ref-type="supplementary-material"}) are shown as the median of triplicate measurements ([Suppl. Fig. 7b](#SD3){ref-type="supplementary-material"}). In the *TET2* mutant group, squares, triangles, diamonds and the star indicate homozygous, hemizygous, heterozygous and biallelic heterozygous mutations, respectively (for detail definition, see [online methods](#SD1){ref-type="supplementary-material"}). The horizontal bar indicates the median for each group. *p*-values for group comparisons were calculated by a two-sided Wilcoxon rank sum test. Patients bearing *TET2* mutations show uniformly low 5-hmC expression levels.](nihms247005f2){#F2}

![Tet2 regulates myeloid differentiation\
**a, b**, *Tet2* shRNA represses *Tet2* mRNA and protein expression. **a**, c-Kit^+^ stem/progenitor cells from bone marrow of C57BL/6 mice were transduced with retroviruses ([Suppl. Fig. 10](#SD3){ref-type="supplementary-material"}). After selection with puromycin for 3 days, *Tet2* mRNA expression was assessed by quantitative RT-PCR. Error bars show the range of duplicates. **b**, HEK293T cells were cotransfected with expression plasmids encoding Myc-tagged Tet2 and retroviral shRNAs. 48 h later, Tet2 protein expression was quantified by anti-Myc immunoblotting of whole cell extracts.\
**c**, Effect of Tet2 depletion on myeloid differentiation. Lin^−^ cells purified from bone marrow of C57BL/6 mice were transduced with control (scramble) or shTet2 retroviruses, then cultured in the presence of 50 ng/ml stem cell factor (SCF), puromycin (2 µg/ml) and cytokines (10 ng/ml) as indicated (also see [Suppl. Fig. 10](#SD3){ref-type="supplementary-material"}). After 4 days, flow cytometric analysis of Mac-1 vs. F4/80 (*left panel*) or CD115 (also known as M-CSFR, *right panel*) was performed. All cells were GFP^+^ at the day of analysis.](nihms247005f3){#F3}

![Relation of 5-hmC levels to DNA methylation status\
**a**, Normalised 5-hmC (CMS) levels in DNA from three different groups: healthy controls (black diamonds), patients with mutant *TET2* (red symbols) and patients with wild type *TET2* (blue circles). Among *TET2* mutants, we distinguish homozygous (squares), hemizygous (triangles), heterozygous (small diamonds) and biallelic heterozygous (star) mutations (for definitions see [Online Methods](#SD1){ref-type="supplementary-material"}). The horizontal bar indicates the median for each group. The number of samples in each group is indicated.\
**b**, Histogram of normalised 5-hmC (CMS) levels in DNA from healthy donors (black diamonds), patients with mutant *TET2* (red rectangles) and patients with wild type *TET2* (blue circles). The frequency was calculated based on a Gaussian kernel estimator. The local minimum between both modes was used as a threshold (vertical dotted line) between low and high 5-hmC values.\
**c**, Density of methylation values for healthy controls (black), high 5-hmC samples (blue) and low 5-hmC samples (red) of all sites (*top panel*), sites outside CpG islands (*middle panel*) and sites inside CpG islands (*lower panel*).\
**d**, Boxplot for group-specific methylation for the only two hypermethylated sites (*SP140*, *AIM2*; *top panel*) and the top nine hypomethylated sites (*lower panels*) between healthy controls and low 5-hmC samples (total number of differentially sites was 2512).](nihms247005f4){#F4}
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